Insider Trading Alert - CMLP, IVZ, V, DXCM And OPK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 13, 2013, 134 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $14.34 to $156,760,095.40.

Highlighted Stocks Traded by Insiders:

Crestwood Midstream Partners (CMLP) - FREE Research Report

Lumpkins David who is Director at Crestwood Midstream Partners bought 10,000 shares at $21.31 on Dec. 13, 2013. Following this transaction, the Director owned 10,913 shares meaning that the stake was reduced by 1095.29% with the 10,000-share transaction.

The shares most recently traded at $21.35, up $0.04, or 0.18% since the insider transaction. Historical insider transactions for Crestwood Midstream Partners go as follows:

  • 4-Week # shares sold: 3,627
  • 12-Week # shares sold: 3,627
  • 24-Week # shares sold: 3,627

The average volume for Crestwood Midstream Partners has been 852,900 shares per day over the past 30 days. Crestwood Midstream Partners has a market cap of $3.6 billion and is part of the basic materials sector and energy industry. Shares are down 7.19% year-to-date as of the close of trading on Wednesday.

Crestwood Midstream Partners LP primarily engages in the gathering, processing, treating, compressing, transporting, and selling natural gas in the United States. The company operates in four segments: Barnett, Fayetteville, Granite Wash, and Marcellus. The stock currently has a dividend yield of 7.84%. The company has a P/E ratio of 59.0. Currently there are 6 analysts that rate Crestwood Midstream Partners a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CMLP - FREE

TheStreet Quant Ratings rates Crestwood Midstream Partners as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Crestwood Midstream Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Invesco (IVZ) - FREE Research Report

Meadows Colin who is Senior Managing Director at Invesco sold 20,000 shares at $34.85 on Dec. 13, 2013. Following this transaction, the Senior Managing Director owned 365,086 shares meaning that the stake was reduced by 5.19% with the 20,000-share transaction.

The shares most recently traded at $34.39, down $0.46, or 1.34% since the insider transaction. Historical insider transactions for Invesco go as follows:

  • 4-Week # shares sold: 3,975
  • 12-Week # shares sold: 338,975
  • 24-Week # shares sold: 338,975

The average volume for Invesco has been 4.2 million shares per day over the past 30 days. Invesco has a market cap of $15.7 billion and is part of the financial sector and financial services industry. Shares are up 32.77% year-to-date as of the close of trading on Wednesday.

Invesco Ltd. is a publicly owned investment manager. It primarily provides its services to institutional clients including major public entities, corporations, unions, non-profit organizations, endowments, foundations, pension funds, and financial institutions. The stock currently has a dividend yield of 2.54%. The company has a P/E ratio of 19.3. Currently there are 8 analysts that rate Invesco a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IVZ - FREE

TheStreet Quant Ratings rates Invesco as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Invesco Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Visa (V) - FREE Research Report

Fernandez-Carbajal Francisco Javier who is Director at Visa sold 40,600 shares at $201.69 on Dec. 13, 2013. Following this transaction, the Director owned 3,056 shares meaning that the stake was reduced by 93% with the 40,600-share transaction.

The shares most recently traded at $203.44, up $1.75, or 0.86% since the insider transaction. Historical insider transactions for Visa go as follows:

  • 4-Week # shares sold: 4,154
  • 12-Week # shares sold: 14,406
  • 24-Week # shares sold: 55,101

The average volume for Visa has been 3.0 million shares per day over the past 30 days. Visa has a market cap of $101.0 billion and is part of the financial sector and financial services industry. Shares are up 35.68% year-to-date as of the close of trading on Wednesday.

Visa Inc., a payments technology company, engages in the operation of retail electronic payments network worldwide. It facilitates commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities. The stock currently has a dividend yield of 0.8%. The company has a P/E ratio of 26.3. Currently there are 15 analysts that rate Visa a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on V - FREE

TheStreet Quant Ratings rates Visa as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Visa Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

DexCom (DXCM) - FREE Research Report

Augustinos Nicholas who is Director at DexCom sold 11,321 shares at $34.40 on Dec. 13, 2013. Following this transaction, the Director owned 11,130 shares meaning that the stake was reduced by 50.43% with the 11,321-share transaction.

The shares most recently traded at $34.60, up $0.20, or 0.56% since the insider transaction. Historical insider transactions for DexCom go as follows:

  • 4-Week # shares sold: 43,925
  • 12-Week # shares sold: 76,225
  • 24-Week # shares sold: 76,225

The average volume for DexCom has been 632,700 shares per day over the past 30 days. DexCom has a market cap of $2.4 billion and is part of the health care sector and health services industry. Shares are up 146.95% year-to-date as of the close of trading on Wednesday.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. Currently there are 8 analysts that rate DexCom a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXCM - FREE

TheStreet Quant Ratings rates DexCom as a sell. The area that we feel has been the company's primary weakness has been its disappointing return on equity. Get the full DexCom Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 50,000 shares at $9.44 on Dec. 13, 2013. Following this transaction, the CEO & Chairman owned 137.3 million shares meaning that the stake was reduced by 0.04% with the 50,000-share transaction.

The shares most recently traded at $9.42, down $0.02, or 0.25% since the insider transaction.

The average volume for Opko Health has been 4.7 million shares per day over the past 30 days. Opko Health has a market cap of $4.7 billion and is part of the health care sector and health services industry. Shares are up 139.09% year-to-date as of the close of trading on Wednesday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

How Investors Can Generate Yields from MLPs

How Investors Can Generate Yields from MLPs

Trade-Ideas: Crestwood Midstream Partners (CMLP) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Crestwood Midstream Partners (CMLP) Is Today's Weak On High Relative Volume Stock

Crestwood Midstream Partners (CMLP) Is Strong On High Volume Today

Crestwood Midstream Partners (CMLP) Is Strong On High Volume Today

Today's Weak On High Volume Stock: Crestwood Midstream Partners (CMLP)

Today's Weak On High Volume Stock: Crestwood Midstream Partners (CMLP)

What To Sell: 3 Sell-Rated Dividend Stocks MUX, CMLP, KRO

What To Sell: 3 Sell-Rated Dividend Stocks MUX, CMLP, KRO